Particulars (Rs. in Crores) | Q2FY23 | Q2FY22 | YoY (%) | Q1FY23 | QoQ (%) |
---|---|---|---|---|---|
Revenue from Operations | 1855.00 | 1987.51 | -7.00% | 2255.00 | -18.00% |
EBITDA | 621.51 | 818.07 | -24.00% | 847.00 | -27.00% |
EBITDA Margin (%) | 34.00% | 41.00% | 37.56% | ||
Profit After Tax | 493.99 | 606.46 | -19.00% | 702.00 | -30.00% |
Earnings Per Share (Rs.) | 18.60 | 22.84 | 26.00 |
Source: Company Filings; StockAxis Research
Quarterly result highlights Q2FY23
Divis Labs posted weak earnings for the quarter ended Q2FY23, mainly because of
the slowdown in custom synthesis and erosion in margins that dragged the overall
performance for the company. Consolidated revenues de-grew 7% to Rs.1855 cr on a
YoY basis.
The custom synthesis segment revenue (43% of revenues) dropped by 26% YoY to Rs.797 cr YoY due to reduced sales of Molnupiravir on a high base of COVID sales. Nutraceuticals sales fell 3% YoY at Rs.163 cr. Generic API business, however, posted a growth of 20%.
EBITDA recorded at Rs.622 declined sharply due to lower revenues and elevated raw material costs. EBITDA Margins for the quarter stood at 34%, contracting sharply by 700 bps on a YoY basis as it was impacted by the change in product mix, higher other expenses and negative operating leverage. The company has been impacted by higher prices of solvents (toluene) along with higher energy costs resulting into weak operational show by the company.
Due to lower revenues and weak operational performance by the company, PAT also declined by 19% to Rs.494 cr on a YoY basis.
Conference Call Highlights
Divis growth prospects across businesses remain positive and will propel growth in the future. Given its established capabilities, backward integration, quality focus, and scale benefits, as well as major capacity expansion plans going on stream, the company is well-positioned to meet increasing demand from global big pharma companies. Divi’s remains preferred play on Indian CRAMS and API given its strong execution track record.
At CMP of Rs.3414 as on November 07, 2022, the stock is trading at 26x FY25E and we maintain hold on the stock.
Particulars (Rs. in Crores) | Q2FY23 | Q2FY22 | YoY (%) | Q1FY23 | QoQ (%) |
---|---|---|---|---|---|
Revenue from Operations | 1855.00 | 1987.51 | -7.00% | 2255.00 | -18.00% |
COGS | 674.62 | 654.83 | 812.00 | ||
Gross Profit | 1180.38 | 1332.68 | -11.00% | 1443.00 | -18.00% |
Gross Margin (%) | 64.00% | 67.00% | 64.00% | ||
Employee Benefit Expenses | 232.12 | 223.98 | 246.00 | ||
Other Expenses | 326.75 | 290.63 | 349.00 | ||
EBITDA | 621.51 | 818.07 | -24.00% | 847.00 | -27.00% |
EBITDA Margin (%) | 34.00% | 41.00% | 37.56% | ||
Depreciation | 85.73 | 77.35 | 84.00 | ||
EBIT | 535.78 | 740.72 | -28.00% | 763.00 | -30.00% |
EBIT Margin (%) | 29.00% | 37.00% | 33.84% | ||
Finance Cost | 0.17 | 0.21 | 0.00 | ||
Other Income | 80.00 | 19.11 | 88.00 | ||
Profit Before Tax | 615.61 | 759.62 | -19.00% | 851.00 | -28.00% |
Tax | 121.62 | 153.16 | 149.00 | ||
Effective Tax Rate (%) | 20.00% | 20.00% | 18.00% | ||
Profit After Tax | 493.99 | 606.46 | -19.00% | 702.00 | -30.00% |
PAT Margin (%) | 27.00% | 31.00% | 31.14% | ||
Earnings Per Share (Rs.) | 18.60 | 22.84 | 26.00 |
Source: Company Filings; StockAxis Research
Year End March (Rs. in Crores) | 2021 | 2022 | 2023E | 2024E | 2025E |
---|---|---|---|---|---|
Net Sales | 6969.40 | 8959.80 | 8707.30 | 10057.50 | 11350.00 |
Growth % | 29.20% | 28.60% | -2.80% | 15.50% | 12.90% |
Expenditure | |||||
Material Cost | 2376.70 | 2967.50 | 2960.50 | 3218.40 | 3632.00 |
Employee Cost | 825.80 | 946.20 | 1131.90 | 1206.90 | 1362.00 |
Other Expenses | 905.90 | 1163.90 | 1219.00 | 1377.90 | 12.90% |
EBITDA | 2861.10 | 3882.30 | 3395.80 | 4254.30 | 4891.90 |
Growth % | 56.90% | 35.70% | -12.50% | 25.30% | 15.00% |
EBITDA Margin | 41.10% | 43.30% | 39.00% | 42.30% | 43.00% |
Depreciation & Amortization | 255.60 | 311.50 | 324.00 | 331.00 | 356.00 |
EBIT | 2605.50 | 3570.80 | 3071.80 | 3923.30 | 4535.90 |
EBIT Margin % | 37.40% | 39.90% | 35.30% | 39.00% | 40.00% |
Other Income | 62.70 | 113.80 | 135.00 | 127.00 | 145.00 |
Interest & Finance Charges | 2.10 | 0.80 | 1.80 | 2.20 | 3.20 |
Profit Before Tax - Before Exceptional | 2666.00 | 3683.80 | 3205.00 | 4048.10 | 4677.70 |
Profit Before Tax | 2666.00 | 3683.80 | 3205.00 | 4048.10 | 15.60% |
Tax Expense | 681.80 | 724.00 | 806.70 | 1018.90 | 1178.80 |
Effective Tax rate | 25.60% | 19.70% | 25.20% | 25.20% | 25.20% |
Net Profit | 1984.30 | 2959.80 | 2398.30 | 3029.20 | 3498.90 |
Growth % | 44.20% | 49.20% | -19.00% | 26.30% | 15.50% |
Net Profit Margin | 28.50% | 33.00% | 27.50% | 30.10% | 31.00% |
Consolidated Net Profit | 1984.30 | 2959.80 | 2398.30 | 3029.20 | 3498.90 |
Growth % | 44.20% | 49.20% | -19.00% | 26.30% | 15.50% |
As of March (Rs. in Crores) | 2021 | 2022 | 2023E | 2024E | 2025E |
---|---|---|---|---|---|
Share Capital | 53.10 | 53.10 | 53.10 | 53.10 | 53.10 |
Total Reserves | 9241.50 | 11675.10 | 13542.50 | 16040.80 | 19008.80 |
Shareholders' Funds | 9294.60 | 11728.20 | 13595.60 | 16093.90 | 19061.90 |
Non Current Liabilities | |||||
Long Term Burrowing | - | - | 41.00 | 51.20 | 63.40 |
Deferred Tax Assets / Liabilities | 334.80 | 421.40 | 421.40 | 421.40 | 421.40 |
Long Term Provisions | 25.40 | 26.70 | 26.70 | 26.70 | 26.70 |
Current Liabilities | - | ||||
Short Term Borrowings | 0.40 | 0.40 | 0.40 | 0.40 | 0.40 |
Trade Payables | 763.20 | 796.00 | 847.10 | 899.70 | 1026.40 |
Other Current Liabilities | 340.40 | 330.30 | 330.30 | 330.30 | 330.30 |
Short Term Provisions | 624.40 | 68.00 | 68.00 | 68.00 | 68.00 |
Total Equity & Liabilities | 11386.90 | 13373.80 | 15333.30 | 17894.40 | 21001.30 |
Assets | - | ||||
Net Block | 3703.90 | 4080.40 | 4381.40 | 4750.40 | 5194.40 |
Non Current Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Long Term Loans & Advances | 172.60 | 173.60 | 173.60 | 173.60 | 173.60 |
Current Assets | |||||
Currents Investments | - | - | - | - | - |
Inventories | 2145.20 | 2828.60 | 2783.20 | 2956.10 | 3372.40 |
Sundry Debtors | 1676.50 | 2423.90 | 2541.20 | 2699.00 | 3079.20 |
Cash and Bank | 2156.00 | 2818.90 | 4641.70 | 6503.10 | 8368.70 |
Short Term Loans and Advances | 749.90 | 217.00 | 217.00 | 217.00 | 217.00 |
Total Assets | 11386.90 | 13373.80 | 15333.20 | 17894.50 | 21001.40 |
Year End March (Rs. in Crores) | 2021 | 2022 | 2023E | 2024E | 2025E |
---|---|---|---|---|---|
Profit After Tax | 1984.30 | 2959.80 | 2398.30 | 3029.20 | 3498.90 |
Depreciation | 255.60 | 311.50 | 324.00 | 331.00 | 356.00 |
Changes in Working Capital | -264.10 | -1272.30 | -20.80 | -278.20 | -669.70 |
Cash From Operating Activities | 1946.90 | 1999.00 | 2701.50 | 3082.00 | 3185.10 |
Purchase of Fixed Assets | -910.20 | -713.00 | -600.00 | -700.00 | -800.00 |
Free Cash Flows | 1036.70 | 1286.00 | 2101.50 | 2382.00 | 2385.10 |
Cash Flow from Investing Activities | 75.10 | -713.00 | 1253.10 | -699.90 | -799.90 |
Increase / (Decrease) in Loan Funds | - | 37.80 | 3.20 | 10.20 | 11.20 |
Cash from Financing Activities | -34.90 | -493.10 | -527.70 | -520.70 | -519.70 |
Net Cash Inflow / Outflow | 1987.20 | 792.90 | 3426.90 | 1861.40 | 1865.50 |
Opening Cash & Cash Equivalents | 43.20 | 2030.30 | 1214.80 | 4641.70 | 6503.10 |
Closing Cash & Cash Equivalent | 2030.30 | 1214.80 | 4641.70 | 6503.10 | 8368.70 |
Year End March | 2021 | 2022 | 2023E | 2024E | 2025E |
---|---|---|---|---|---|
Basic EPS | 74.80 | 111.50 | 90.30 | 114.10 | 131.80 |
Diluted EPS | 74.80 | 111.50 | 90.30 | 114.10 | 131.80 |
Cash EPS (Rs) | 84.40 | 123.20 | 102.60 | 126.60 | 145.20 |
DPS | 20.00 | 20.00 | 20.00 | 20.00 | 20.00 |
Book value (Rs/share) | 350.10 | 441.80 | 512.20 | 606.30 | 718.10 |
ROCE (%) Post Tax | 23.90% | 28.20% | 18.90% | 20.40% | 19.90% |
ROE (%) | 21.30% | 25.20% | 17.60% | 18.80% | 18.40% |
Inventory Days | 105.00 | 130.00 | 115.00 | 115.00 | 115.00 |
Receivable Days | 80.90 | 110.00 | 105.00 | 105.00 | 105.00 |
Payable Days | 35.50 | 45.00 | 35.00 | 35.00 | 35.00 |
PE | 48.50 | 32.80 | 37.80 | 29.90 | 25.90 |
P/BV | 10.30 | 8.30 | 6.70 | 5.60 | 4.80 |
EV/EBITDA | 32.90 | 24.30 | 25.30 | 19.80 | 16.80 |
Dividend Yield (%) | 0.60% | 0.50% | 0.60% | 0.60% | 0.60% |
P/Sales | 13.80 | 10.80 | 10.40 | 9.00 | 8.00 |
Net debt/Equity | - | - | - | - | - |
Net Debt/ EBITDA | -0.80 | -0.70 | -1.40 | -1.50 | -1.70 |